Meta-analysis of hsCRP's Effect on Cardiovascular Outcome among GLP-1RAs–Based Clinical Trials

Related

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• Orforglipron matches insulin glargine on cardiovascular safety

  Lancet · 4 Oct 2026

• Semaglutide improved heart artery function in pigs

  Research Square · 8 Oct 2026

• A triple-target drug cut body weight by up to 19.7% in a trial

  Cell Metabolism · 8 Oct 2026